In this episode, Martin discusses Google's latest earnings results and shares his outlook for the company's future performance. He also examines ServiceNow, explaining why he believes it may represent a value opportunity, and revisits his bearish thesis on CAPR, outlining the factors that continue to support his short position.

In this episode, Martin discusses a quantitative investing approach that he uses to compare and rank investment opportunities. He also shares his perspective on Kimi K3, analyzes Sionna (SION), and reviews Biohaven and Cue, examining each company's business, valuation, competitive position, and the factors he believes could influence their investment outlook.

This compilation brings together Martin’s discussions on preparing for periods of heightened market volatility and uncertainty. Across a range of clips, he examines changing market conditions, portfolio positioning, risk management, and stock-specific investment ideas, while explaining the reasoning behind his outlook and the strategies he believes investors should consider when navigating rapidly changing markets.

In this episode, Martin discusses his expectations for the market heading into the new trading week and revisits his outlook on Micron, examining whether he still considers the stock an attractive investment. He also comments on the possibility of a buyout involving Abivax and analyzes Abbott (ABT) and Exelixis, discussing their businesses, valuations, and the factors he believes could influence their future performance.

In this episode, Martin discusses his outlook on the memory semiconductor industry and explains why he believes investor attention may be shifting toward quantum computing. He also shares his perspective on CoreWeave and PayPal, and analyzes TenX, Ultragenyx, and Evotec, examining each company's business, valuation, and the factors he believes could influence their future performance.

In this episode, Martin examines Micron's recent performance and discusses whether the company's stock has reached a cyclical peak or may be approaching a bottom. He analyzes supply and demand trends in the memory semiconductor market, competitive dynamics, valuation, and the factors he believes could influence Micron's outlook in the coming quarters.

In this episode, Martin discusses potential acquisition targets for Apple and considers how such a move could affect the company's long-term strategy. He also shares his perspective on a possible long position in Oracle, examines developments involving Stripe, and analyzes Celcuity, Electrovaya, and Adicet, discussing each company's business, valuation, and investment outlook.

In this episode, Martin discusses a sharp decline in IBM and considers what it could mean for the broader technology sector. He also provides an analysis of Lumentum (LITE), examining the company's business, competitive position, and outlook, before discussing Adobe's recent stock performance and the factors he believes are contributing to its relative strength.

In this episode, Martin provides an extended analysis of Insmed, examining the company’s commercial products, clinical pipeline, competitive position, and potential growth opportunities. He also discusses the assumptions behind the company’s valuation, the risks surrounding its drug-development programs, and the factors that could shape the stock’s longer-term outlook.

In this episode, Martin discusses recent weakness in IBM and considers whether it could signal broader challenges for other companies in the sector. He also provides a detailed analysis of Bristol Myers Squibb (BMY), examining its business, product portfolio, and valuation, before reviewing Insmed (INSM) and sharing his perspective on the company's prospects and investment outlook.